Disappointing Nerlynx sales shows Pierre Fabre timing is everything | Evaluate
Pierre Fabre engagements | NERLYNX
Puma Biotechnology | Evaluate
Fight against cancer : our therapeutic responses | Pierre Fabre
Fight against cancer : our therapeutic responses | Pierre Fabre
Pierre Fabre amends license agreement with Puma Biotechnology - European Biotechnology
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma Biotechnology, Pierre Fabre enter into Exclusive License Agreement
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Pierre Fabre and ValenzaBio collaborate on anti-IGF-1R antibody for TE
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies
Pierre Fabre & NERLYNX commercialisation | Nerlynx
Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China | Business Wire
Partners of the Pierre Fabre Group: from health to beauty
Puma and CANBridge cancel licensing deal for $20m
Partners of the Pierre Fabre Group: from health to beauty
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma Bio: Sifting Through The Q4 Earnings Report (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration | Business Wire
Puma licences breast cancer therapy Nerlynx to Pierre Fabre in Europe
Puma Biotech Expands Pierre Fabre License to Add Countries
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in
Accord entre Pierre Fabre et Puma Biotechnology
